Business Context and Reporting Period
This Form 8-K Current Report, dated March 31, 2016, details a significant executive leadership transition at AngioDynamics, Inc. The filing reports the appointment of James C. Clemmer as President and Chief Executive Officer, effective April 4, 2016, succeeding Joseph M. DeVivo, who departed the company on March 31, 2016 to pursue other interests.
Key Financial Metrics and Compensation
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or debt levels. The primary financial data relates to the new CEO's compensation package:
- Base Salary: $625,000 per year.
- Target Annual Bonus: 100% of base salary (beginning fiscal year ending May 31, 2017).
- Inducement Equity Grants (April 4, 2016):
- 250,000 performance shares (payout 0-200% based on total shareholder return).
- Option to purchase 200,000 shares (strike price equal to closing price on April 4, 2016; 4-year vesting).
- 50,000 restricted stock units (4-year vesting).
- Additional Benefits: $1,500 monthly car allowance, $75,000 relocation allowance, and up to $15,000 legal fee reimbursement.
Material Changes
The material change reported is the departure of the long-serving CEO, Joseph M. DeVivo (in office since September 2011), and the immediate appointment of James C. Clemmer. Mr. Clemmer brings prior experience as President of the Medical Supplies segment at Covidien plc and Group President at Kendall Healthcare. He has also been appointed to the Company's Board of Directors.
Outlook, Risks, and Contingencies
Employment Terms: The initial employment term is two years, subject to one-year extensions. The filing outlines specific severance provisions:
- Standard Termination: If terminated without Cause or for Good Reason, Mr. Clemmer is eligible for 12 months of base salary, a prorated bonus, 12 months of COBRA coverage, and continued equity vesting for 12 months.
- Change in Control: A separate Change in Control Agreement provides for a lump sum cash payment equal to 2.5 times annual base salary, plus bonuses and vacation pay, if employment is terminated in connection with a change in control.
Future Compensation Policy: The Board intends for the CEO's annual equity grant (post-inducement period) to be valued at 225% of base salary, split between stock options, restricted stock units, and performance shares.
Investor Verification Checklist
- Verify the exact vesting schedules and performance metrics for the 250,000 performance shares granted to Mr. Clemmer.
- Confirm the strike price of the 200,000 stock options based on the April 4, 2016 closing price.
- Review the definitions of "Cause" and "Good Reason" in the Employment Agreement to understand termination triggers.
- Assess the potential dilution impact of the 500,000 total equity units granted to the new CEO.
- Monitor future filings for the Company's fiscal year 2017 results to evaluate the new leadership's initial performance.